Post by iamaverb on Mar 18, 2015 17:27:00 GMT
Looks like an opportunity for some one on one.
Late Breaking Abstract to Highlight Enhanced Anti-Tumor Efficacy of ADXS-HPV (ADXS11-001) in Combination with OX40 and GITR Co-Stimulatory Molecule Monoclonal Antibodies
Additional Late Breaking Abstract to Demonstrate Delay of Tumor Progression and Prolonged Overall Survival in Study of ADXS-HER2 in Combination with Radiation in Canine Osteosarcoma
Advaxis (ADXS) to Host AACR Research Reception on April 21, 2015 at 6:30 p.m., EDT
PRINCETON, N.J., March 18, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc.(ADXS) , a cancer immunotherapy company, today announced that three abstracts revealing new data for Advaxis's(ADXS) proprietary Lm-LLO cancer immunotherapy platform have been selected for poster presentations at the 2015 American Association for Cancer Research (AACR) Annual Meeting, April 18 – 22, 2015, at the Pennsylvania Convention Center in Philadelphia, Pennsylvania.
The first poster, selected as a late breaking abstract, is entitled "Agnostic antibodies to co-stimulatory molecules, OX40 and GITR, significantly enhance the anti-tumor efficacy of Listeria monocytogenes (Lm-LLO)-based immunotherapy." The poster will be presented by Samir Khleif, M.D., Director of the State of Georgia Cancer Center, Georgia Regents University Cancer Center (GRU), during the Late-Breaking Research: Immunology session, on Tuesday, April 21, 2015, from 1:00 PM – 5:00 PM E.T. (Section 26; Poster Board #13; Abstract #LB-229).
The second poster, also selected as a late-breaking abstract, is entitled "Recombinant HER2/Neu expressing Lm-LLO immunotherapy combined with radiation safely delays tumor progression and prolongs overall survival in a phase I clinical study in canine osteosarcoma." The poster is scheduled to be presented by principal investigator Nicola J. Mason, B.Vet.Med., Ph.D., Assistant Professor of Medicine and Pathobiology at the University of Pennsylvania School of Veterinary Medicine, during the Late-Breaking Research: Clinical Research/Endocrinology session, on Monday, April 20, 2015, from 1:00 PM – 5:00 PM E.T. (Section 40; Poster Board #7; Abstract #LB-113).
The third poster, entitled, "Anti-tumor therapeutic effects in mice treated with Listeria monocytogenes (Lm-LLO) immunotherapy in combination with PD-L1," highlights preclinical work demonstrating that ADXS-HPV (ADXS11-001) yields significantly better anti-tumor activity when combined with an anti-PD-L1 antibody, than the anti-PD-L1 antibody alone. The poster will be presented by Poonam Molli, Ph.D., Senior Scientist, Advaxis, Inc.(ADXS), during the Tumor Vaccines poster session, on Monday, April 20, 2015, from 1:00 PM – 5:00 PM E.T. (Section 26; Abstract #2513).
Advaxis (ADXS) also announced that the company will host an AACR Research Reception at The Ritz-Carlton, Philadelphia on April 21, 2015 at 6:30 p.m., EDT. Additional details about the event and registration information will be made available via Advaxis's(ADXS) corporate website: www.advaxis.com.
Late Breaking Abstract to Highlight Enhanced Anti-Tumor Efficacy of ADXS-HPV (ADXS11-001) in Combination with OX40 and GITR Co-Stimulatory Molecule Monoclonal Antibodies
Additional Late Breaking Abstract to Demonstrate Delay of Tumor Progression and Prolonged Overall Survival in Study of ADXS-HER2 in Combination with Radiation in Canine Osteosarcoma
Advaxis (ADXS) to Host AACR Research Reception on April 21, 2015 at 6:30 p.m., EDT
PRINCETON, N.J., March 18, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc.(ADXS) , a cancer immunotherapy company, today announced that three abstracts revealing new data for Advaxis's(ADXS) proprietary Lm-LLO cancer immunotherapy platform have been selected for poster presentations at the 2015 American Association for Cancer Research (AACR) Annual Meeting, April 18 – 22, 2015, at the Pennsylvania Convention Center in Philadelphia, Pennsylvania.
The first poster, selected as a late breaking abstract, is entitled "Agnostic antibodies to co-stimulatory molecules, OX40 and GITR, significantly enhance the anti-tumor efficacy of Listeria monocytogenes (Lm-LLO)-based immunotherapy." The poster will be presented by Samir Khleif, M.D., Director of the State of Georgia Cancer Center, Georgia Regents University Cancer Center (GRU), during the Late-Breaking Research: Immunology session, on Tuesday, April 21, 2015, from 1:00 PM – 5:00 PM E.T. (Section 26; Poster Board #13; Abstract #LB-229).
The second poster, also selected as a late-breaking abstract, is entitled "Recombinant HER2/Neu expressing Lm-LLO immunotherapy combined with radiation safely delays tumor progression and prolongs overall survival in a phase I clinical study in canine osteosarcoma." The poster is scheduled to be presented by principal investigator Nicola J. Mason, B.Vet.Med., Ph.D., Assistant Professor of Medicine and Pathobiology at the University of Pennsylvania School of Veterinary Medicine, during the Late-Breaking Research: Clinical Research/Endocrinology session, on Monday, April 20, 2015, from 1:00 PM – 5:00 PM E.T. (Section 40; Poster Board #7; Abstract #LB-113).
The third poster, entitled, "Anti-tumor therapeutic effects in mice treated with Listeria monocytogenes (Lm-LLO) immunotherapy in combination with PD-L1," highlights preclinical work demonstrating that ADXS-HPV (ADXS11-001) yields significantly better anti-tumor activity when combined with an anti-PD-L1 antibody, than the anti-PD-L1 antibody alone. The poster will be presented by Poonam Molli, Ph.D., Senior Scientist, Advaxis, Inc.(ADXS), during the Tumor Vaccines poster session, on Monday, April 20, 2015, from 1:00 PM – 5:00 PM E.T. (Section 26; Abstract #2513).
Advaxis (ADXS) also announced that the company will host an AACR Research Reception at The Ritz-Carlton, Philadelphia on April 21, 2015 at 6:30 p.m., EDT. Additional details about the event and registration information will be made available via Advaxis's(ADXS) corporate website: www.advaxis.com.
Also wondering,,any mention of Latin America? Wonder if that fell off the table?